NYBC stocks the probiotic Florastor, which is Saccharomyces boulardi lyo (lyo = freeze dried, the best means discovered for preserving the effectiveness of this agent). Saccharomyces boulardii, a yeast first investigated by French microbiologist Henri Boulard in Indochina in the 1920s, has been widely researched and distributed over the last fifty years, though it has a longer history of use in Europe than in the US.
We’re glad that Florastor has become available in the United States in the last five years, since before that we were obliged to import this pharmaceutical grade probiotic from Europe; the US versions of Saccharomyces boulardii often seemed quite a bit less effective, perhaps because the European production techniques were more advanced.
Here are the main indications/conditions for which Saccharomyces boulardii has been investigated:
A controlled study found a significant reduction in symptoms of diarrhea in adults taking 250mg of S. boulardii twice a day for five days or until symptoms were relieved.
Irritable Bowel Syndrome
A placebo-controlled study found that patients with diarrhea due mainly to irritable bowel syndrome (IBS) had a significant reduction in number and consistency of bowel movements.
Suggested dosage is 250mg twice daily.
Inflammatory Bowel Disease
Additional benefits to inflammatory bowel disease (IBD) patients may be found in 1) prevention of relapse in Crohn’s disease patients currently in remission and 2) benefits to ulcerative colitis patients with moderate symptoms. Suggested dosage is three 250mg capsules a day.
Some evidence for its use in the prophylaxis (prevention) of antibiotic-associated diarrhea (AAD) in adults. Suggested dosage: 250mg twice a day with the standard antibiotic course.
Saccharomyces boulardii was shown to significantly increase the recovery rate of stage IV AIDS patients suffering from diarrhea versus placebo. On average, patients receiving S. boulardii gained weight while the placebo group lost weight over the 18 month study. There were no reported adverse reaction observed in these immunocompromised patients.
Recurrent Clostridium difficile Infection
Two 500mg doses per day of Saccharomyces boulardii when taken with one of two antibiotics (vancomycin or metronidazole) were found to significantly reduce the rate of recurrent Clostridium difficile (pseudomembranous colitis) infection. However, note that significant benefit was not found for prevention of an initial episode of Clostridium difficile-associated disease.
For more on Saccharomyces boulardii, see the NYBC entry:
Note that non-member price is $30, but member price is ONLY $29. (NYBC Membership costs $5, $10, or $25 per year, depending on income.)
Some citations (there are many more, since Saccharomyces boulardii is among the most-studied probiotics):
–Höcher W, Chase D, Hagenhoff G (1990). “Saccharomyces boulardii in acute adult diarrhoea. Efficacy and tolerance of treatment”. Münch Med Wochenschr 132: 188–92.
–McFarland L, Surawicz C, Greenberg R (1994). “A randomised placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease”. J Am Med Assoc 271: 1913–8.
–Maupas J, Champemont P, Delforge M (1983). “Treatment of irritable bowel syndrome with Saccharomyces boulardii: a double blind, placebo controlled study”. Medicine Chirurgie Digestives 12(1): 77–9.
–Guslandi M, Mezzi G, Sorghi M, Testoni PA (2000). “Saccharomyces boulardii in maintenance treatment of Crohn’s disease”. Dig. Dis. Sci. 45 (7): 1462–4. PMID 10961730.
–Guslandi M, Giollo P, Testoni PA (2003). “A pilot trial of Saccharomyces boulardii in ulcerative colitis”. Eur J Gastroenterol Hepatol 15 (6): 697–8. doi:10.1097/01.meg.0000059138.68845.06. PMID 12840682.
–Saint-Marc T, Blehaut H, Musial C, Touraine J (1995). “AIDS related diarrhea: a double-blind trial of Saccharomyces boulardii”. Sem Hôsp Paris 71: 735–41.